UNSPSC 51392602: Metaraminol

This classification denotes an alpha-adrenergic agonist with the molecular formula C9H13NO2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 818U2PZ2EH, chemically known as benzyl alcohol, alpha-(1-aminoethyl)-m-hydroxy-, (-)- but generally known as metaraminol, which bears US NIH Compound Identifier 5906. European Medicines Agency schedules Metaraminol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08815MIG. The term METARAMINOL is an International Non-Proprietary Name.

UNSPSC 51392602 Metaraminol is a Commodity code that covers pharmaceutical products, though recent state and local solicitations show procurement activity focused on naloxone and safe drug deactivation systems rather than metaraminol specifically. State and local health departments, counties, and human services commissions are the primary issuing bodies soliciting under this code, with both direct product purchases and exploratory procurement efforts to establish pharmaceutical sourcing pathways. The work spans routine commodity acquisition—competitive bids for naloxone and related emergency medical supplies with quarterly delivery schedules—and strategic market-research initiatives designed to evaluate alternative pharmaceutical distribution models outside traditional pharmacy benefit managers and wholesalers.

Seminole County, Florida posted an IFB in June 2026 seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually, with a response deadline of July 26, 2023 and quarterly deliveries to the Seminole County Community Health Building in Sanford. The Texas Health and Human Services Commission issued an RFI in April 2026 to solicit vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program, requesting information from vendors on their experience with direct contracting for self-insured employer and state agency health plans and their flexibility to negotiate net-pricing models without rebates. Geographic activity centers on the Southeast and Texas, with the recent opportunities indicating state and county health systems evaluating both off-the-shelf pharmaceutical purchases and novel direct-procurement arrangements to improve prescription fulfillment efficiency and cost management.